Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

3-Substituted Quinolines as RORγt Inverse Agonists.

Tanis VM, Venkatesan H, Cummings MD, Albers M, Kent Barbay J, Herman K, Kummer DA, Milligan C, Nelen MI, Nishimura R, Schlueter T, Scott B, Spurlino J, Wolin R, Woods C, Xue X, Edwards JP, Fourie AM, Leonard K.

Bioorg Med Chem Lett. 2019 Jun 15;29(12):1463-1470. doi: 10.1016/j.bmcl.2019.04.021. Epub 2019 Apr 12.

PMID:
31010722
2.

Structure-Based Macrocycle Design in Small-Molecule Drug Discovery and Simple Metrics To Identify Opportunities for Macrocyclization of Small-Molecule Ligands.

Cummings MD, Sekharan S.

J Med Chem. 2019 Mar 22. doi: 10.1021/acs.jmedchem.8b01985. [Epub ahead of print]

PMID:
30860377
3.

Conformational Sampling of Macrocyclic Drugs in Different Environments: Can We Find the Relevant Conformations?

Poongavanam V, Danelius E, Peintner S, Alcaraz L, Caron G, Cummings MD, Wlodek S, Erdelyi M, Hawkins PCD, Ermondi G, Kihlberg J.

ACS Omega. 2018 Sep 30;3(9):11742-11757. doi: 10.1021/acsomega.8b01379. Epub 2018 Sep 24.

4.

Design and synthesis of a series of bioavailable fatty acid synthase (FASN) KR domain inhibitors for cancer therapy.

Lu T, Schubert C, Cummings MD, Bignan G, Connolly PJ, Smans K, Ludovici D, Parker MH, Meyer C, Rocaboy C, Alexander R, Grasberger B, De Breucker S, Esser N, Fraiponts E, Gilissen R, Janssens B, Peeters D, Van Nuffel L, Vermeulen P, Bischoff J, Meerpoel L.

Bioorg Med Chem Lett. 2018 Jul 1;28(12):2159-2164. doi: 10.1016/j.bmcl.2018.05.014. Epub 2018 May 8.

PMID:
29779975
5.

Identification and biological evaluation of thiazole-based inverse agonists of RORγt.

Gege C, Cummings MD, Albers M, Kinzel O, Kleymann G, Schlüter T, Steeneck C, Nelen MI, Milligan C, Spurlino J, Xue X, Leonard K, Edwards JP, Fourie A, Goldberg SD, Hoffmann T.

Bioorg Med Chem Lett. 2018 May 15;28(9):1446-1455. doi: 10.1016/j.bmcl.2018.03.093. Epub 2018 Apr 3.

PMID:
29631962
6.

Protocols for the Design of Kinase-focused Compound Libraries.

Jacoby E, Wroblowski B, Buyck C, Neefs JM, Meyer C, Cummings MD, van Vlijmen H.

Mol Inform. 2018 May;37(5):e1700119. doi: 10.1002/minf.201700119. Epub 2017 Nov 8.

PMID:
29116686
7.

6-Substituted quinolines as RORγt inverse agonists.

Barbay JK, Cummings MD, Abad M, Castro G, Kreutter KD, Kummer DA, Maharoof U, Milligan C, Nishimura R, Pierce J, Schalk-Hihi C, Spurlino J, Tanis VM, Urbanski M, Venkatesan H, Wang A, Woods C, Wolin R, Xue X, Edwards JP, Fourie AM, Leonard K.

Bioorg Med Chem Lett. 2017 Dec 1;27(23):5277-5283. doi: 10.1016/j.bmcl.2017.10.027. Epub 2017 Oct 16.

PMID:
29079472
8.

Identification and structure activity relationships of quinoline tertiary alcohol modulators of RORγt.

Kummer DA, Cummings MD, Abad M, Barbay J, Castro G, Wolin R, Kreutter KD, Maharoof U, Milligan C, Nishimura R, Pierce J, Schalk-Hihi C, Spurlino J, Urbanski M, Venkatesan H, Wang A, Woods C, Xue X, Edwards JP, Fourie AM, Leonard K.

Bioorg Med Chem Lett. 2017 May 1;27(9):2047-2057. doi: 10.1016/j.bmcl.2017.02.044. Epub 2017 Feb 21.

PMID:
28318945
9.

Oxysterols are agonist ligands of RORγt and drive Th17 cell differentiation.

Soroosh P, Wu J, Xue X, Song J, Sutton SW, Sablad M, Yu J, Nelen MI, Liu X, Castro G, Luna R, Crawford S, Banie H, Dandridge RA, Deng X, Bittner A, Kuei C, Tootoonchi M, Rozenkrants N, Herman K, Gao J, Yang XV, Sachen K, Ngo K, Fung-Leung WP, Nguyen S, de Leon-Tabaldo A, Blevitt J, Zhang Y, Cummings MD, Rao T, Mani NS, Liu C, McKinnon M, Milla ME, Fourie AM, Sun S.

Proc Natl Acad Sci U S A. 2014 Aug 19;111(33):12163-8. doi: 10.1073/pnas.1322807111. Epub 2014 Aug 4.

10.

Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor.

Rosenquist Å, Samuelsson B, Johansson PO, Cummings MD, Lenz O, Raboisson P, Simmen K, Vendeville S, de Kock H, Nilsson M, Horvath A, Kalmeijer R, de la Rosa G, Beumont-Mauviel M.

J Med Chem. 2014 Mar 13;57(5):1673-93. doi: 10.1021/jm401507s. Epub 2014 Feb 14.

PMID:
24446688
11.

Discovery and early development of TMC647055, a non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase.

Cummings MD, Lin TI, Hu L, Tahri A, McGowan D, Amssoms K, Last S, Devogelaere B, Rouan MC, Vijgen L, Berke JM, Dehertogh P, Fransen E, Cleiren E, van der Helm L, Fanning G, Nyanguile O, Simmen K, Van Remoortere P, Raboisson P, Vendeville S.

J Med Chem. 2014 Mar 13;57(5):1880-92. doi: 10.1021/jm401396p. Epub 2013 Nov 8.

PMID:
24144360
12.

Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202).

Lenz O, Vijgen L, Berke JM, Cummings MD, Fevery B, Peeters M, De Smedt G, Moreno C, Picchio G.

J Hepatol. 2013 Mar;58(3):445-51. doi: 10.1016/j.jhep.2012.10.028. Epub 2012 Nov 7.

PMID:
23142061
13.

TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage.

Devogelaere B, Berke JM, Vijgen L, Dehertogh P, Fransen E, Cleiren E, van der Helm L, Nyanguile O, Tahri A, Amssoms K, Lenz O, Cummings MD, Clayton RF, Vendeville S, Raboisson P, Simmen KA, Fanning GC, Lin TI.

Antimicrob Agents Chemother. 2012 Sep;56(9):4676-84. doi: 10.1128/AAC.00245-12. Epub 2012 Jun 18.

14.

Finger loop inhibitors of the HCV NS5b polymerase. Part II. Optimization of tetracyclic indole-based macrocycle leading to the discovery of TMC647055.

Vendeville S, Lin TI, Hu L, Tahri A, McGowan D, Cummings MD, Amssoms K, Canard M, Last S, Van den Steen I, Devogelaere B, Rouan MC, Vijgen L, Berke JM, Dehertogh P, Fransen E, Cleiren E, van der Helm L, Fanning G, Van Emelen K, Nyanguile O, Simmen K, Raboisson P.

Bioorg Med Chem Lett. 2012 Jul 1;22(13):4437-43. doi: 10.1016/j.bmcl.2012.04.113. Epub 2012 Apr 30.

PMID:
22633687
15.

Finger-loop inhibitors of the HCV NS5b polymerase. Part 1: Discovery and optimization of novel 1,6- and 2,6-macrocyclic indole series.

McGowan D, Vendeville S, Lin TI, Tahri A, Hu L, Cummings MD, Amssoms K, Berke JM, Canard M, Cleiren E, Dehertogh P, Last S, Fransen E, Van Der Helm E, Van den Steen I, Vijgen L, Rouan MC, Fanning G, Nyanguile O, Van Emelen K, Simmen K, Raboisson P.

Bioorg Med Chem Lett. 2012 Jul 1;22(13):4431-6. doi: 10.1016/j.bmcl.2012.03.097. Epub 2012 Apr 3.

PMID:
22542193
16.

Structure-based macrocyclization yields hepatitis C virus NS5B inhibitors with improved binding affinities and pharmacokinetic properties.

Cummings MD, Lin TI, Hu L, Tahri A, McGowan D, Amssoms K, Last S, Devogelaere B, Rouan MC, Vijgen L, Berke JM, Dehertogh P, Fransen E, Cleiren E, van der Helm L, Fanning G, Van Emelen K, Nyanguile O, Simmen K, Raboisson P, Vendeville S.

Angew Chem Int Ed Engl. 2012 May 7;51(19):4637-40. doi: 10.1002/anie.201200110. Epub 2012 Mar 30. No abstract available.

PMID:
22473861
17.

Structure-based site of metabolism prediction for cytochrome P450 2D6.

Moors SL, Vos AM, Cummings MD, Van Vlijmen H, Ceulemans A.

J Med Chem. 2011 Sep 8;54(17):6098-105. doi: 10.1021/jm2006468. Epub 2011 Aug 5.

PMID:
21797232
18.

Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.

Goethals O, Van Ginderen M, Vos A, Cummings MD, Van Der Borght K, Van Wesenbeeck L, Feyaerts M, Verheyen A, Smits V, Van Loock M, Hertogs K, Schols D, Clayton RF.

Antiviral Res. 2011 Aug;91(2):167-76. doi: 10.1016/j.antiviral.2011.05.011. Epub 2011 Jun 12.

PMID:
21669228
19.

2'-Deoxy-2'-spirocyclopropylcytidine revisited: a new and selective inhibitor of the hepatitis C virus NS5B polymerase.

Jonckers TH, Lin TI, Buyck C, Lachau-Durand S, Vandyck K, Van Hoof S, Vandekerckhove LA, Hu L, Berke JM, Vijgen L, Dillen LL, Cummings MD, de Kock H, Nilsson M, Sund C, Rydegård C, Samuelsson B, Rosenquist A, Fanning G, Van Emelen K, Simmen K, Raboisson P.

J Med Chem. 2010 Nov 25;53(22):8150-60. doi: 10.1021/jm101050a. Epub 2010 Oct 29.

PMID:
21033671
20.

Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance.

Hare S, Vos AM, Clayton RF, Thuring JW, Cummings MD, Cherepanov P.

Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20057-62. doi: 10.1073/pnas.1010246107. Epub 2010 Oct 28.

21.

In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.

Lenz O, Verbinnen T, Lin TI, Vijgen L, Cummings MD, Lindberg J, Berke JM, Dehertogh P, Fransen E, Scholliers A, Vermeiren K, Ivens T, Raboisson P, Edlund M, Storm S, Vrang L, de Kock H, Fanning GC, Simmen KA.

Antimicrob Agents Chemother. 2010 May;54(5):1878-87. doi: 10.1128/AAC.01452-09. Epub 2010 Feb 22.

22.

Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/NS4A protease target.

Cummings MD, Lindberg J, Lin TI, de Kock H, Lenz O, Lilja E, Felländer S, Baraznenok V, Nyström S, Nilsson M, Vrang L, Edlund M, Rosenquist A, Samuelsson B, Raboisson P, Simmen K.

Angew Chem Int Ed Engl. 2010 Feb 22;49(9):1652-5. doi: 10.1002/anie.200906696. No abstract available. Erratum in: Angew Chem Int Ed Engl. 2010 Apr 26;49(19):3250.

PMID:
20166108
23.

1a/1b subtype profiling of nonnucleoside polymerase inhibitors of hepatitis C virus.

Nyanguile O, Devogelaere B, Vijgen L, Van den Broeck W, Pauwels F, Cummings MD, De Bondt HL, Vos AM, Berke JM, Lenz O, Vandercruyssen G, Vermeiren K, Mostmans W, Dehertogh P, Delouvroy F, Vendeville S, VanDyck K, Dockx K, Cleiren E, Raboisson P, Simmen KA, Fanning GC.

J Virol. 2010 Mar;84(6):2923-34. doi: 10.1128/JVI.01980-09. Epub 2010 Jan 13.

24.

Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein.

Roymans D, De Bondt HL, Arnoult E, Geluykens P, Gevers T, Van Ginderen M, Verheyen N, Kim H, Willebrords R, Bonfanti JF, Bruinzeel W, Cummings MD, van Vlijmen H, Andries K.

Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):308-13. doi: 10.1073/pnas.0910108106. Epub 2009 Dec 4.

25.

Structure-based design of a benzodiazepine scaffold yields a potent allosteric inhibitor of hepatitis C NS5B RNA polymerase.

Vandyck K, Cummings MD, Nyanguile O, Boutton CW, Vendeville S, McGowan D, Devogelaere B, Amssoms K, Last S, Rombauts K, Tahri A, Lory P, Hu L, Beauchamp DA, Simmen K, Raboisson P.

J Med Chem. 2009 Jul 23;52(14):4099-102. doi: 10.1021/jm9005548.

PMID:
19507864
26.

1,5-Benzodiazepine inhibitors of HCV NS5B polymerase.

McGowan D, Nyanguile O, Cummings MD, Vendeville S, Vandyck K, Van den Broeck W, Boutton CW, De Bondt H, Quirynen L, Amssoms K, Bonfanti JF, Last S, Rombauts K, Tahri A, Hu L, Delouvroy F, Vermeiren K, Vandercruyssen G, Van der Helm L, Cleiren E, Mostmans W, Lory P, Pille G, Van Emelen K, Fanning G, Pauwels F, Lin TI, Simmen K, Raboisson P.

Bioorg Med Chem Lett. 2009 May 1;19(9):2492-6. doi: 10.1016/j.bmcl.2009.03.035. Epub 2009 Mar 14.

PMID:
19342234
27.

1,5-benzodiazepines, a novel class of hepatitis C virus polymerase nonnucleoside inhibitors.

Nyanguile O, Pauwels F, Van den Broeck W, Boutton CW, Quirynen L, Ivens T, van der Helm L, Vandercruyssen G, Mostmans W, Delouvroy F, Dehertogh P, Cummings MD, Bonfanti JF, Simmen KA, Raboisson P.

Antimicrob Agents Chemother. 2008 Dec;52(12):4420-31. doi: 10.1128/AAC.00669-08. Epub 2008 Oct 13.

28.

Biphenylsulfonyl-thiophene-carboxamidine inhibitors of the complement component C1s.

Travins JM, Ali F, Huang H, Ballentine SK, Khalil E, Hufnagel HR, Pan W, Gushue J, Leonard K, Bone RF, Soll RM, DesJarlais RL, Crysler CS, Ninan N, Kirkpatrick J, Cummings MD, Huebert N, Molloy CJ, Gaul M, Tomczuk BE, Subasinghe NL.

Bioorg Med Chem Lett. 2008 Mar 1;18(5):1603-6. doi: 10.1016/j.bmcl.2008.01.064. Epub 2008 Jan 19.

PMID:
18242991
29.

Structural basis for elastolytic substrate specificity in rodent alpha-chymases.

Kervinen J, Abad M, Crysler C, Kolpak M, Mahan AD, Masucci JA, Bayoumy S, Cummings MD, Yao X, Olson M, de Garavilla L, Kuo L, Deckman I, Spurlino J.

J Biol Chem. 2008 Jan 4;283(1):427-36. Epub 2007 Oct 31.

30.

Processing of small molecule databases for automated docking.

Cummings MD, Gibbs AC, DesJarlais RL.

Med Chem. 2007 Jan;3(1):107-13. Review.

PMID:
17266630
31.

Universal screening methods and applications of ThermoFluor.

Cummings MD, Farnum MA, Nelen MI.

J Biomol Screen. 2006 Oct;11(7):854-63. Epub 2006 Aug 30. Review.

PMID:
16943390
32.

Novel 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists with improved cellular activity.

Leonard K, Marugan JJ, Raboisson P, Calvo R, Gushue JM, Koblish HK, Lattanze J, Zhao S, Cummings MD, Player MR, Maroney AC, Lu T.

Bioorg Med Chem Lett. 2006 Jul 1;16(13):3463-8. Epub 2006 May 2.

PMID:
16647257
33.

Enantiomerically pure 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists.

Marugan JJ, Leonard K, Raboisson P, Gushue JM, Calvo R, Koblish HK, Lattanze J, Zhao S, Cummings MD, Player MR, Schubert C, Maroney AC, Lu T.

Bioorg Med Chem Lett. 2006 Jun 15;16(12):3115-20. Epub 2006 Apr 21.

PMID:
16630722
34.

Substituted 1,4-benzodiazepine-2,5-diones as alpha-helix mimetic antagonists of the HDM2-p53 protein-protein interaction.

Cummings MD, Schubert C, Parks DJ, Calvo RR, LaFrance LV, Lattanze J, Milkiewicz KL, Lu T.

Chem Biol Drug Des. 2006 Mar;67(3):201-5. Review.

PMID:
16611213
35.

Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design.

Parks DJ, LaFrance LV, Calvo RR, Milkiewicz KL, Marugán JJ, Raboisson P, Schubert C, Koblish HK, Zhao S, Franks CF, Lattanze J, Carver TE, Cummings MD, Maguire D, Grasberger BL, Maroney AC, Lu T.

Bioorg Med Chem Lett. 2006 Jun 15;16(12):3310-4. Epub 2006 Apr 4.

PMID:
16600594
36.

A novel series of arylsulfonylthiophene-2-carboxamidine inhibitors of the complement component C1s.

Subasinghe NL, Travins JM, Ali F, Huang H, Ballentine SK, Marugán JJ, Khalil E, Hufnagel HR, Bone RF, DesJarlais RL, Crysler CS, Ninan N, Cummings MD, Molloy CJ, Tomczuk BE.

Bioorg Med Chem Lett. 2006 Apr 15;16(8):2200-4. Epub 2006 Feb 3.

PMID:
16460935
37.

Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo.

Koblish HK, Zhao S, Franks CF, Donatelli RR, Tominovich RM, LaFrance LV, Leonard KA, Gushue JM, Parks DJ, Calvo RR, Milkiewicz KL, Marugán JJ, Raboisson P, Cummings MD, Grasberger BL, Johnson DL, Lu T, Molloy CJ, Maroney AC.

Mol Cancer Ther. 2006 Jan;5(1):160-9.

38.

Azepanone-based inhibitors of human cathepsin L.

Marquis RW, James I, Zeng J, Trout RE, Thompson S, Rahman A, Yamashita DS, Xie R, Ru Y, Gress CJ, Blake S, Lark MA, Hwang SM, Tomaszek T, Offen P, Head MS, Cummings MD, Veber DF.

J Med Chem. 2005 Nov 3;48(22):6870-8.

PMID:
16250645
39.

Affinity assays for decrypting protein targets of unknown function.

Todd MJ, Cummings MD, Nelen MI.

Drug Discov Today Technol. 2005 Autumn;2(3):267-73. doi: 10.1016/j.ddtec.2005.08.015.

PMID:
24981946
40.

Structure-based design, synthesis, and biological evaluation of novel 1,4-diazepines as HDM2 antagonists.

Raboisson P, Marugán JJ, Schubert C, Koblish HK, Lu T, Zhao S, Player MR, Maroney AC, Reed RL, Huebert ND, Lattanze J, Parks DJ, Cummings MD.

Bioorg Med Chem Lett. 2005 Apr 1;15(7):1857-61.

PMID:
15780621
41.

Docking: successes and challenges.

Mohan V, Gibbs AC, Cummings MD, Jaeger EP, DesJarlais RL.

Curr Pharm Des. 2005;11(3):323-33. Review.

PMID:
15723628
42.

Comparison of automated docking programs as virtual screening tools.

Cummings MD, DesJarlais RL, Gibbs AC, Mohan V, Jaeger EP.

J Med Chem. 2005 Feb 24;48(4):962-76.

PMID:
15715466
43.

Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells.

Grasberger BL, Lu T, Schubert C, Parks DJ, Carver TE, Koblish HK, Cummings MD, LaFrance LV, Milkiewicz KL, Calvo RR, Maguire D, Lattanze J, Franks CF, Zhao S, Ramachandren K, Bylebyl GR, Zhang M, Manthey CL, Petrella EC, Pantoliano MW, Deckman IC, Spurlino JC, Maroney AC, Tomczuk BE, Molloy CJ, Bone RF.

J Med Chem. 2005 Feb 24;48(4):909-12.

PMID:
15715460
44.

1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR.

Parks DJ, Lafrance LV, Calvo RR, Milkiewicz KL, Gupta V, Lattanze J, Ramachandren K, Carver TE, Petrella EC, Cummings MD, Maguire D, Grasberger BL, Lu T.

Bioorg Med Chem Lett. 2005 Feb 1;15(3):765-70.

PMID:
15664854
45.

Decrypting the biochemical function of an essential gene from Streptococcus pneumoniae using ThermoFluor technology.

Carver TE, Bordeau B, Cummings MD, Petrella EC, Pucci MJ, Zawadzke LE, Dougherty BA, Tredup JA, Bryson JW, Yanchunas J Jr, Doyle ML, Witmer MR, Nelen MI, DesJarlais RL, Jaeger EP, Devine H, Asel ED, Springer BA, Bone R, Salemme FR, Todd MJ.

J Biol Chem. 2005 Mar 25;280(12):11704-12. Epub 2005 Jan 5.

46.

A novel series of potent and selective small molecule inhibitors of the complement component C1s.

Subasinghe NL, Ali F, Illig CR, Jonathan Rudolph M, Klein S, Khalil E, Soll RM, Bone RF, Spurlino JC, DesJarlais RL, Crysler CS, Cummings MD, Morris PE Jr, Kilpatrick JM, Sudhakara Babu Y.

Bioorg Med Chem Lett. 2004 Jun 21;14(12):3043-7.

PMID:
15149641
47.

Structure of the C-terminally truncated human ProMMP9, a gelatin-binding matrix metalloproteinase.

Elkins PA, Ho YS, Smith WW, Janson CA, D'Alessio KJ, McQueney MS, Cummings MD, Romanic AM.

Acta Crystallogr D Biol Crystallogr. 2002 Jul;58(Pt 7):1182-92. Epub 2002 Jun 20.

PMID:
12077439
48.

Azepanone-based inhibitors of human and rat cathepsin K.

Marquis RW, Ru Y, LoCastro SM, Zeng J, Yamashita DS, Oh HJ, Erhard KF, Davis LD, Tomaszek TA, Tew D, Salyers K, Proksch J, Ward K, Smith B, Levy M, Cummings MD, Haltiwanger RC, Trescher G, Wang B, Hemling ME, Quinn CJ, Cheng HY, Lin F, Smith WW, Janson CA, Zhao B, McQueney MS, D'Alessio K, Lee CP, Marzulli A, Dodds RA, Blake S, Hwang SM, James IE, Gress CJ, Bradley BR, Lark MW, Gowen M, Veber DF.

J Med Chem. 2001 Apr 26;44(9):1380-95.

PMID:
11311061
49.

Fragment-based modeling of NAD binding to the catalytic subunits of diphtheria and pertussis toxins.

Cummings MD, Hart TN, Read RJ.

Proteins. 1998 May 15;31(3):282-98.

PMID:
9593199
50.

Modeling the carbohydrate-binding specificity of pig edema toxin.

Cummings MD, Ling H, Armstrong GD, Brunton JL, Read RJ.

Biochemistry. 1998 Feb 17;37(7):1789-99.

PMID:
9485304

Supplemental Content

Loading ...
Support Center